FLOW CYTOMETRY, CD 22

The Flow Cytometry CD22 Test is a specialized immunophenotyping assay used to detect and measure the expression of CD22, a cell surface protein primarily found on B lymphocytes. CD22 functions as a regulatory molecule involved in B-cell activation, maturation, and immune response modulation. Because of its strong association with B cells, CD22 serves as an important marker in the diagnosis and classification of various hematological malignancies.

Flow cytometry technology allows rapid and precise analysis of thousands of cells, helping identify CD22-positive cell populations and determine their immunophenotypic characteristics. CD22 is commonly included in comprehensive flow cytometry panels used for evaluating B-cell leukemias, lymphomas, lymphoproliferative disorders, and immune system abnormalities.

The test helps distinguish B-cell lineage from other cell types and contributes to accurate disease classification. It is frequently performed on peripheral blood, bone marrow aspirates, lymph node specimens, or other clinically appropriate samples.

Benefits of the Test

• Identifies B-cell populations accurately
• Assists in leukemia and lymphoma diagnosis
• Supports immunophenotypic classification of B-cell disorders
• Helps detect abnormal B-cell populations
• Assists in disease monitoring and treatment planning
• Provides valuable diagnostic and prognostic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD22 testing for:

• Suspected B-cell leukemia
• Suspected B-cell lymphoma
• Hairy Cell Leukemia evaluation
• Chronic Lymphocytic Leukemia (CLL) assessment
• B-cell lymphoproliferative disorder investigation
• Abnormal lymphocyte counts
• Bone marrow disorder evaluation
• Comprehensive immunophenotyping studies

The test helps identify abnormal B-cell populations and supports accurate diagnosis and classification.

Preparation Before Test

The test may require:

• Peripheral blood sample
• Bone marrow aspirate
• Lymph node tissue
• Body fluid specimen
• Other clinically relevant samples

Preparation generally includes:

• No fasting is required
• Inform your physician about ongoing treatments
• Follow laboratory collection instructions

The specimen is analyzed using advanced multiparameter flow cytometry technology.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on panel complexity and laboratory workflow.

Who Should Take This Test?

• Patients with suspected leukemia
• Individuals with suspected lymphoma
• Patients with abnormal blood counts
• Individuals undergoing bone marrow evaluation
• Patients with B-cell lymphoproliferative disorders
• Individuals referred by hematologists or oncologists

Flow Cytometry CD22 testing is an important component of modern hematology diagnostics and B-cell immunophenotyping.

Clinical Significance

CD22 expression is commonly observed in:

• Normal B Lymphocytes
• B-cell Acute Lymphoblastic Leukemia (B-ALL)
• Chronic Lymphocytic Leukemia (CLL)
• Hairy Cell Leukemia
• Non-Hodgkin Lymphoma
• B-cell Lymphoproliferative Disorders
• Mature B-cell Neoplasms

Abnormal CD22-positive populations may indicate B-cell malignancies and contribute to disease classification and therapeutic decision-making.

Important Note

CD22 is typically interpreted alongside other B-cell markers such as CD19, CD20, CD23, CD10, CD5, CD45, Kappa Light Chains, and Lambda Light Chains. Comprehensive interpretation by a hematopathologist is necessary for accurate diagnosis and clinical management.